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plicing and
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substantial proportion of idiopathic heart failure (HF)
esults from inherited forms of dilated cardiomyopathy
DCM). To date, over 40 different genes or genetic loci have
een associated with DCM, and although each genetic cause is
tself rare, in aggregate these explain up to 15% to 20% of HF
n the general population (1,2). Insights from primary cardio-
yopathies are beginning to inform our understanding of basic
echanisms in HF, but it remains to be seen whether these
pecific pathways operate in acquired forms.
See page 930
The discovery of mutations in genes encoding compo-
ents of the dystrophin associated glycoprotein (DAG)
omplex and in the actin and desmin genes raised the
ossibility of a “final common pathway” for DCM amenable
o genetic diagnosis (3). However, although cytoskeletal
bnormalities are prominent, recent work has implicated
ultiple pathological mechanisms in DCM, even down-
tream of a single mutation (1). Mutations might exert their
ffects in cardiomyocytes not only through disruption of force
ransmission, but also through perturbed sarcolemmal repair,
berrant assembly of macromolecular complexes in membrane
icrodomains, reorganization of subcellular architecture, or
hrough altered susceptibility to viral infection (1,4,5). Disrup-
ion of these same pathways might also lead to disease through
emote effects on other cell types, such as smooth muscle,
hich contribute to the final DCM phenotype (6).
This complex pathophysiologic picture is reinforced by
linical “overlap syndromes” in which DCM segregates in
amilies with hypertrophic cardiomyopathy, arrhythmogenic
ight ventricular cardiomyopathy, or atrial fibrillation (1,7,8).
enetic evaluation has identified mutations in genes encoding
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiology Division and Cardiovascular Research Center, Massachu-p
etts General Hospital, Boston, Massachusetts; and the ‡Centre for Cardiology In
he Young, The Heart Hospital, London, United Kingdom.arcomeric proteins, desmosomal proteins, or ion channels in
uch families, but the modifiers leading to the final clinical
leiotropy are unknown. Interestingly, recent work in animal
odels has uncovered fundamental interactions between early
ardiac function and developmental programs in the patterning
f adult cardiovascular physiology (9). These and other genetic
r epigenetic modifiers may partly explain the limited success
f genotype–phenotype correlation (1,10). The apparently
iverse biology of the DCM genes identified to date implicate
ultiple independent molecular and cellular pathways in the
nal HF phenotype. Discriminating primary from secondary
ffects in the investigation of HF is confounded by presenta-
ion only after the so-called “fetal gene program” has been
riggered and systemic neurohormonal activation has devel-
ped (1,2). Ongoing work applying functional genomics and
ther novel technologies to DCM might uncover further
iscrete etiologic entities, but it is unclear whether unifying
olecular themes will emerge.
In this issue of the Journal, Brauch et al. (11) elegantly
xploit the power of human genetics to identify a novel gene
nderlying 1 form of DCM. Brauch et al. (11) first mapped the
ene in a family characterized by sudden death with interstitial
nd subendocardial fibrosis to chromosome 10q25, then
creened positional candidate genes within this locus. This
ffort identified mutations in a single exon of the gene
ncoding a ribonucleic acid (RNA) binding motif protein,
nown as RBM20, in each of the linked families as well as in
ultiple probands. Where available, family members of these
robands were tested, revealing further evidence of RBM20
utations associated with DCM and supporting the pathoge-
icity of these sequence abnormalities. Ultimately, mutations
n exon 9 of RBM20 were found in 3% of all DCM cases
ested, and in over 13% of those with a history of sudden
eath (11).
The discovery of mutations in this regulatory protein pre-
ents a novel entry point into the biology of human HF. The
echanisms through which mutations in a single exon in
BM20 result in DCM are not immediately apparent. The
BM proteins are components of the spliceosome, a complex
f specialized small RNAs and proteins that removes the
ntronic sequences from pre-messenger ribonucleic acid
mRNA) (12,13). The ninth exon of RBM20 encodes part of
domain rich in arginine and serine residues (the RS domain)
hat is known to interact directly with intronic sequences in the
re-mRNA, mediate protein–protein interactions within the
pliceosome, and participate in alternative splicing (14). New
NA sequencing techniques have revealed the extent to which
lternative splicing is critical for generation of diversity at an
NA and a protein level from the limited number of genes in
he genome (15). Switch-like regulation of opposing functions
r differentially trafficked isoforms across hundreds of genes
an be generated by the complex interplay of available exons
nd splicing machinery. Such an effect in trans is not without
recedent in DCM. The mutant mRNA in myotonic dystro-
hy is known to displace CUG binding protein from other
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September 1, 2009:942–3 Splicing and Dilated Cardiomyopathyre-mRNAs, potentially disrupting several pathways (16). In
ddition, in mice the general alternative splicing factor/splicing
actor 2 (ASF/SF2) has been directly implicated in the transi-
ion between fetal and adult gene programs within the heart
17). Whether RBM20 acts in this same manner is not yet
nown, but it will be intriguing to explore possible insights into
he pathologic activation of the cardiac fetal gene program in
uture work in this area. Further investigation of the role of
BM20 is likely to be accelerated by emerging technologies. It
ill be important to define the range of transcripts whose
plicing is regulated by RBM20, the specificity of intronic
arget sequences, and the upstream factors determining the
ocation and timing of RBM20 expression. This information
ill illuminate the full spectrum of downstream pathways
nvolved in the etiology of DCM. Given the large number of
S proteins on the human Y chromosome, it will also be
nteresting to explore the role of sex-specific splicing programs
n DCM and in acquired HF (14).
The discovery of RBM20 as a causal gene serves to
mphasize that, although the concept of a single “final
ommon pathway” does not apply in DCM, current genetic
nd genomic technologies offer the potential to define the
omplete repertoire of pathways perturbed in this disease
15). Understanding each cardiomyopathy in terms of such
lobal networks and their dynamics, a systems-level analysis
f HF, is now within reach. As noted in the preceding text,
he predictive utility of genotyping has been limited to date,
nd binary genetic categories fail to capture the disparate
raded risks for contractile dysfunction, dilation, conduction
isease, and arrhythmias in each patient (1). Only if we can
efine the net effect of a primary genetic defect in the
ontext of the genetic, epigenetic, and environmental mod-
fiers pertinent in the individual are we likely to be able to
igorously predict outcomes. The complexity of genetic
isease, exemplified by the discovery of RBM20, suggests
hat we must move toward the characterization of multiple
hysiologic and molecular pathways in every patient.
eprint requests and correspondence: Dr. William J. McKenna,
entre for Cardiology In The Young (CITY), The Heart Hospi-
al, 16-18 Westmoreland Street, London W1G 8PH, United
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